XML 29 R17.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Stock-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2024
Retirement Benefits [Abstract] |
Stock-Based Compensation | Note 11 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. A total of 1,835,970 shares of common stock of PAVmed are reserved for issuance under the PAVmed 2014 Equity Plan, with 68,495 shares available for grant as of March 31, 2024. The share reservation is not diminished by a total of 66,720 PAVmed Inc. stock options and restricted stock awards granted outside the PAVmed 2014 Equity Plan as of March 31, 2024. In January 2024, the number of shares available for grant was increased by 432,452 in accordance with the evergreen provisions of the plan. Note 11 — Stock-Based Compensation - continued PAVmed Stock Options PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options
|  | Number of Stock Options |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Term (Years) |  |  | Intrinsic Value(2) |
Outstanding stock options at December 31, 2023 |  |  | 1,192,458 |  |  | $ | 26.18 |  |  |  | 7.3 |  |  | $ | — |
Granted(1) |  |  | 74,500 |  |  | $ | 2.30 |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  | $ | — |  |  |  |  |  |  |  |  |
Forfeited |  |  | (23,025 | ) |  | $ | 10.32 |  |  |  |  |  |  |  |  |
Outstanding stock options at March 31, 2024(3) |  |  | 1,243,933 |  |  | $ | 25.04 |  |  |  | 7.0 |  |  | $ | 17 |
Vested and exercisable stock options at March 31, 2024 |  |  | 799,947 |  |  | $ | 34.11 |  |  |  | 6.0 |  |  | $ | — |
(1) | Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
(2) | The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of March 31, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.
(3) | The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of March 31, 2024 and December 31, 2023.
On February 22, 2024, the Company granted 59,500 stock options under the PAVmed Inc 2014 Equity Plan with a weighted average exercise price of $1.85. Each such option will vest one-third after one year then ratably over the next eight quarters. In addition, on February 22, 2024, a total of 390,000 restricted stock awards were granted to the Board of Directors under the PAVmed 2014 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $0.7 million, which was measured using the respective grant date quoted closing price per share of PAVmed Inc. common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest ratably on an annual basis over a three year period with the initial annual vesting date of November 30, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. PAVmed Restricted Stock Awards PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity
|  | Number of Restricted Stock Awards |  |  | Weighted Average Grant Date Fair Value |
Unvested restricted stock awards as of December 31, 2023 |  |  | 70,527 |  |  | $ | 38.77 |
Granted |  |  | 390,000 |  |  |  | 1.85 |
Vested |  |  | — |  |  |  | — |
Forfeited |  |  | — |  |  |  | — |
Unvested restricted stock awards as of March 31, 2024 |  |  | 460,527 |  |  | $ | 7.50 |
Note 11 — Stock-Based Compensation - continued Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. A total of 14,324,038 shares of common stock of Lucid Diagnostics are reserved for issuance under the Lucid Diagnostics 2018 Equity Plan, with 2,680,508 shares available for grant as of March 31, 2024. The share reservation is not diminished by a total of 423,300 stock options and 50,000 restricted stock awards granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2024. In January 2024, the number of shares available for grant was increased by 2,680,038 in accordance with the evergreen provisions of the plan. Lucid Diagnostics Stock Options Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options
|  | Number of Stock Options |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Term (Years) |  |  | Intrinsic Value(2) |
Outstanding stock options at December 31, 2023 |  |  | 5,504,383 |  |  | $ | 2.00 |  |  |  | 8.5 |  |  | $ | 765 |
Granted(1) |  |  | 3,000,000 |  |  | $ | 1.25 |  |  |  |  |  |  |  |  |
Exercised |  |  | (3,333 | ) |  | $ | 1.31 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (168,337 | ) |  | $ | 1.57 |  |  |  |  |  |  |  |  |
Outstanding stock options at March 31, 2024(3) |  |  | 8,332,713 |  |  | $ | 1.74 |  |  |  | 8.8 |  |  | $ | 195 |
Vested and exercisable stock options at March 31, 2024 |  |  | 2,655,413 |  |  | $ | 2.29 |  |  |  | 7.6 |  |  | $ | 195 |
(1) | Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
(2) | The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of March 31, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
(3) | The outstanding stock options presented in the table above are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2024 and December 31, 2023.
On February 22, 2024, Lucid granted 2,895,000 stock options under the Lucid Diagnostics Inc 2018 Equity Plan with a weighted average exercise price of $1.25. Each option will vest one-third after one year then ratably over the next eight quarters. Note 11 — Stock-Based Compensation - continued Lucid Diagnostics Restricted Stock Awards Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity
|  | Number of Restricted Stock Awards |  |  | Weighted Average Grant Date Fair Value |
Unvested restricted stock awards as of December 31, 2023 |  |  | 2,337,440 |  |  | $ | 8.99 |
Granted |  |  | — |  |  |  | — |
Vested |  |  | (26,912 | ) |  |  | 4.56 |
Forfeited |  |  | (13,088 | ) |  |  | 4.56 |
Unvested restricted stock awards as of March 31, 2024 |  |  | 2,297,440 |  |  | $ | 9.07 |
Subsequent to March 31, 2024, in May 2024, a total of 1,600,000 restricted stock awards were granted to management under the Lucid Diagnostics 2018 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $1.5 million, which was measured using the respective grant date quoted closing price per share of Lucid Diagnostics Inc. common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest on a single vest date of May 20, 2026. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Consolidated Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized by each of PAVmed and Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense
|  | 2024 |  |  | 2023 |
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Cost of revenue |  | $ | 36 |  |  | $ | 23 |
Sales and marketing expenses |  |  | 403 |  |  |  | 444 |
General and administrative expenses |  |  | 1,078 |  |  |  | 3,588 |
Research and development expenses |  |  | 365 |  |  |  | 364 |
Total stock-based compensation expense |  | $ | 1,882 |  |  | $ | 4,419 |
Note 11 — Stock-Based Compensation - continued Stock-Based Compensation Expense Recognized by Lucid Diagnostics As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics, inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics
|  | 2024 |  |  | 2023 |
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Lucid Diagnostics 2018 Equity Plan – cost of revenue |  | $ | 25 |  |  | $ | 12 |
Lucid Diagnostics 2018 Equity Plan – sales and marketing |  |  | 271 |  |  |  | 223 |
Lucid Diagnostics 2018 Equity Plan – general and administrative |  |  | 328 |  |  |  | 2,512 |
Lucid Diagnostics 2018 Equity Plan – research and development |  |  | 120 |  |  |  | 70 |
PAVmed 2014 Equity Plan - cost of revenue |  |  | 11 |  |  |  | 7 |
PAVmed 2014 Equity Plan - sales and marketing |  |  | 79 |  |  |  | 133 |
PAVmed 2014 Equity Plan - general and administrative |  |  | 2 |  |  |  | 156 |
PAVmed 2014 Equity Plan - research and development |  |  | 97 |  |  |  | 95 |
Total stock-based compensation expense – recognized by Lucid Diagnostics |  | $ | 933 |  |  | $ | 3,208 |
Total stock-based compensation expense |  | $ | 933 |  |  | $ | 3,208 |
The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense
|  | Unrecognized Expense |  |  | Weighted Average Remaining Service Period (Years) |
PAVmed 2014 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 2,732 |  |  |  | 1.8 |
Restricted Stock Awards |  | $ | 745 |  |  |  | 2.7 |
Lucid Diagnostics 2018 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 5,282 |  |  |  | 2.3 |
Restricted Stock Awards |  | $ | 941 |  |  |  | 2.0 |
Note 11 — Stock-Based Compensation - continued Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $1.46 per share and $5.25 per share during the three month periods ended March 31, 2024 and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Expected term of stock options (in years) |  |  | 5.8 |  |  |  | 5.7 |
Expected stock price volatility |  |  | 90 | % |  |  | 88 | %
Risk free interest rate |  |  | 4.3 | % |  |  | 3.7 | %
Expected dividend yield |  |  | — | % |  |  | — | %
Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.84 per share and $0.87 per share during the three month periods ended March 31, 2024 and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Expected term of stock options (in years) |  |  | 5.7 |  |  |  | 5.6 |
Expected stock price volatility |  |  | 74 | % |  |  | 75 | %
Risk free interest rate |  |  | 4.3 | % |  |  | 3.7 | %
Expected dividend yield |  |  | — | % |  |  | — | %
PAVmed Inc. Employee Stock Purchase Plan (“PAVmed ESPP”) A total of 34,332 shares and 38,216 shares of common stock of the Company were purchased for proceeds of approximately $62 and $182, on March 31, 2024 and 2023, respectively, under the PAVmed ESPP. The March 31, 2023 purchase was partially settled through the redeployment of 12,590 shares of treasury stock. The PAVmed ESPP has a total reserve of 300,001 shares of common stock of PAVmed of which 139,863 shares are available for issue as of March 31, 2024. In January 2024, the number of shares available-for-issue was increased by 166,667 in accordance with the evergreen provisions of the plan. Lucid Diagnostics Inc. Employee Stock Purchase Plan (“Lucid ESPP”) A total of 511,884 shares and 231,987 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $353 and $276 on March 31, 2024 and 2023, respectively, under the Lucid ESPP. The Lucid ESPP has a total reserve of 1,500,000 shares of common stock of Lucid Diagnostics of which 395,886 shares are available for issue as of March 31, 2024. In January 2024, the Lucid board authorized an increase in the number of shares available for issue by 500,000.

X
- Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CompensationAndRetirementDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration